Published in J Urol on August 01, 2001
Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol (2009) 1.00
Re: Response of hormone refractory prostate cancer to lycopene. J Urol (2002) 0.75
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem (1988) 2.15
Hormonal risk factors in testicular cancer. A case-control study. Am J Epidemiol (1986) 1.97
Development of the human gastrointestinal tract. A review. Gastroenterology (1976) 1.93
Ferritin and the response to oxidative stress. Biochem J (2001) 1.88
A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol (1996) 1.69
Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother (1993) 1.65
Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol (1985) 1.65
Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem (1995) 1.61
Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A (1990) 1.59
Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol (2000) 1.58
Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res (1999) 1.54
Reproducibility of three different methods of measuring baroreflex sensitivity in normal subjects. Clin Sci (Lond) (1998) 1.43
A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1992) 1.37
Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci U S A (1991) 1.36
Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest (1993) 1.36
Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol (1988) 1.35
Bladder cancer, 1996. CA Cancer J Clin (1996) 1.32
Escherichia coli DNA helicase II is active as a monomer. J Biol Chem (1999) 1.32
Validity of bioelectric impedance for body composition assessment in children. J Appl Physiol (1985) (1989) 1.27
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains. J Antimicrob Chemother (1991) 1.18
The biology and treatment of superficial bladder cancer. J Clin Oncol (1984) 1.18
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
Quinolone resistance in veterinary isolates of Salmonella. J Antimicrob Chemother (1994) 1.16
Detection of small changes in body composition by dual-energy x-ray absorptiometry. Am J Clin Nutr (1993) 1.14
Recombinant ferritin: modulation of subunit stoichiometry in bacterial expression systems. Protein Eng (1997) 1.13
Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun (1990) 1.12
Brain metastases from transitional cell carcinoma of the bladder. J Urol (1988) 1.10
FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. Mol Cell Biol (1995) 1.08
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07
Role of H and L subunits in mouse ferritin. J Biol Chem (1996) 1.07
Tumor necrosis factor-alpha and interleukin 1-alpha regulate transferrin receptor in human diploid fibroblasts. Relationship to the induction of ferritin heavy chain. J Biol Chem (1991) 1.06
Resistance exercise training is associated with decreases in serum low-density lipoprotein cholesterol levels in premenopausal women. Arch Intern Med (1993) 1.06
Inactivation of DNA mismatch repair by increased expression of yeast MLH1. Mol Cell Biol (2001) 1.03
Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res (1993) 1.02
Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. Cancer Control (2001) 1.01
Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol (1983) 0.99
p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis (2001) 0.98
Evidence for two mechanisms by which tumor necrosis factor kills cells. J Biol Chem (1989) 0.98
Mechanism of action of lomefloxacin. Antimicrob Agents Chemother (1990) 0.97
A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys (2001) 0.96
Articular changes in the knee of the adult rat after prolonged immobilization in extension. Clin Orthop Relat Res (1968) 0.96
Cartilage changes after experimental relief of contact in the knee joint of the mature rat. Clin Orthop Relat Res (1969) 0.95
Serum markers in germ cell neoplasms. Hematol Oncol Clin North Am (1991) 0.95
Tumor cell cytotoxicity of a novel metal chelator. Blood (1998) 0.95
Iron and ferritin in inflammation and cancer. Adv Inorg Biochem (1994) 0.95
Preferential repression of the H subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts. J Biol Chem (1993) 0.94
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants. J Cell Biochem (1993) 0.94
The Structure of the Upper End of the Humerus with Reference to Osteoporotic Changes in Senescence Leading to Fractures. Can Med Assoc J (1963) 0.93
Extralymphatic Hodgkin's disease. Prognosis and response to therapy. Am J Med (1981) 0.93
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Human H-kininogen is a ferritin-binding protein. J Biol Chem (1998) 0.92
Adenovirus E1A blocks oxidant-dependent ferritin induction and sensitizes cells to pro-oxidant cytotoxicity. FEBS Lett (1999) 0.91
Activation of the ferritin H enhancer, FER-1, by the cooperative action of members of the AP1 and Sp1 transcription factor families. J Biol Chem (1998) 0.91
Transcriptional regulation of the mouse ferritin H gene. Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity. J Biol Chem (1999) 0.91
Nutrients, body composition and exercise are related to change in bone mineral density in premenopausal women. J Nutr (1995) 0.89
Skeletal complications in a series of human renal allografts. JAMA (1969) 0.89
The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study. J Urol (1985) 0.88
Long-term metabolic effects of urinary diversion: a comparison of myelomeningocele patients managed by clean intermittent catheterization and urinary diversion. J Urol (1992) 0.88
Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol (1993) 0.88
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol (1992) 0.86
Efficient scheduling of cystoscopies in monitoring for recurrent bladder cancer. Med Decis Making (1989) 0.86
Regulation of NF-kappaB and HIV-1 LTR activity in mouse L cells by ultraviolet radiation: LTR trans-activation in a nonirradiated genome in heterokaryons. Exp Cell Res (1997) 0.86
Augmentation by IL-1 alpha of tumor necrosis factor-alpha cytotoxicity in cells transfected with adenovirus E1A. J Immunol (1993) 0.86
Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy. Cancer (1987) 0.86
Tumor necrosis factor-induced c-myc expression in the absence of mitogenesis is associated with inhibition of adipocyte differentiation. Proc Natl Acad Sci U S A (1993) 0.85
Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer (1985) 0.84
Primary osteogenic sarcoma of the bladder. Case report and review of the literature. Cancer (1986) 0.84
The core control system of intracellular iron homeostasis: a mathematical model. J Theor Biol (2012) 0.84
Possible risk of invasive pulmonary aspergillosis with marijuana use during chemotherapy for small cell lung cancer. Drug Intell Clin Pharm (1986) 0.84
Radio frequency ablation of lung metastases from renal cell carcinoma. J Urol (2001) 0.84
Coronary sinus diverticulum containing posteroseptal accessory pathway. Heart (2001) 0.83
Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst (1991) 0.83
Murine ferritin heavy chain: isolation and characterization of a functional gene. Gene (1990) 0.83
Biomarkers associated with prostate cancer progression. J Cell Biochem Suppl (1994) 0.83
The chemotherapy of bladder carcinoma: systemic therapy. Recent Results Cancer Res (1983) 0.83
Separation of massive avascular osteocartilaginous fragment of femoral condyle following renal transplantation. Report of two cases. J Bone Joint Surg Am (1970) 0.82
Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ-cell carcinoma. Ann Intern Med (1984) 0.82
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6. Br J Cancer (1999) 0.82
Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol (1991) 0.82
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer (1985) 0.81
Hormonal control of adipocyte differentiation and adipocyte gene expression. Recent Prog Horm Res (1988) 0.80
Evaluation of mRNA levels by the polymerase chain reaction in small cardiac tissue samples. J Mol Cell Cardiol (1991) 0.80
Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol (1987) 0.80
Development of intestinal adenyl cyclase and its response to cholera enterotoxin. J Clin Invest (1973) 0.80
Response criteria in urologic malignancies. Recent Results Cancer Res (1983) 0.80
The role of iron in the cytotoxicity of tumor necrosis factor. Lymphokine Cytokine Res (1993) 0.79
Recent advances in the treatment of prostate cancer. Ann Oncol (1999) 0.79
Prediction of body composition in premenopausal females from dual-energy X-ray absorptiometry. J Appl Physiol (1985) (1993) 0.79
Sleep apnoea/hypopnoea syndrome: a potential cause of graft failure following heart transplantation. Eur J Cardiothorac Surg (1998) 0.79
Selective inhibition of muscle gene expression by oxidative stress in cardiac cells. J Mol Cell Cardiol (1998) 0.79
Endocrine therapy of prostate cancer. Cancer Treat Res (1998) 0.79
Eustachian tube blockage and Meniere's disease. Arch Otolaryngol (1977) 0.78
Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res (1993) 0.78
Effects of injection site and flow rate on the distribution of injected solutions in an extracorporeal membrane oxygenation circuit. Am J Hosp Pharm (1993) 0.78